After BioNTech SE and Pfizer, Moderna and NIH, 3rd mRNA Covid vaccine player CureVac now partners with fellow German company Bayer...

Infectious diseases have been largely forgotten by Pharma R&D and investors, as chronic diseases, cancer and rare diseases gave better...

Complex logistics ahead for Pfizer and BioNTech vaccine Complex logistics ahead for Pfizer and BioNTech will have to deal with complex...

Usage of Biosimilars has increased significantly in Europe, while usage in the US has been lagging behind. Now, Biosimilars are finally...

The $ 20+ billion Psoriasis treatment market has been dominated by AbbVie's Humira. But things might change soon. After beating J&J’s...

Pharma Industry invest $1 billion to sustain antibiotic pipeline on the verge of collapse. For the past 30 years, antibiotic-resistant...

No major Alzheimer's treatment has been approved since 2003. With some improvement on clinical dementia scale, Biogen's Adacunamab will...

ASCO meeting took place virtually this year due to Covid-19. But it didn't fall short of exciting announcements that will shape the...

Millions of treatments have been delayed during the pandemic. These are not going away and some will become major procedures. Pharma and...

Checkpoint inhibitors against PD-1, PD-L1, CTLA-4 are dramatically improving cancer treatment in defined patient sub-sets. Combining...

Mass-diagnostics, ambulatory procedures, telehealth, web-visits... The COVID-19 outbreak has forced healthcare systems, Pharma and...

As the Biopharma industry in trying to match the pace of the outbreak, let's recap what are industry’s attempts to fight the pandemic....

Fighting coming tsunami of antibiotic resistance that could cause millions of deaths, MIT team uses AI to design Halicin, a novel...

2 recent studies have shown Type 2 Diabetes is reversible, through pharmaceutical and controlled weight-loss. Exciting perspective for...

With 50 million patients globally and no disease-modifying treatment, Alzheimer's disease represents a major unmet need. Following...